Tyme Technologies, Inc. (OTCMKTS:TYMI) Files An 8-K Regulation FD DisclosureItem 7.01. Regulation FD Disclosure.
On June 15, 2017, Tyme Technologies, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original 8-K”) for the purposes of providing an information slide deck used by the Company during a presentation at the the 6th Annual Marcum Microcap Conference. Such presentation has been updated as of today in connection with presentations that may be given from time to time to investor groups. This amendment to the Original 8-K provides the updated slide presentation, furnished herewith as Exhibit 99.1.
The information furnished to Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Exchange Act. This Current Report (including the exhibit hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.
Item 9.01. Financial Statements and Exhibits.
Set forth below is the exhibit to this Current Report on Form 8-K.
TYME TECHNOLOGIES, INC. Exhibit…To view the full exhibit click here
About Tyme Technologies, Inc. (OTCMKTS:TYMI)
Tyme Technologies, Inc., formerly Global Group Enterprises Corp., conducts majority of its research and development activities and other business operations, through its subsidiary, Tyme Inc. (Tyme). Tyme is a clinical-stage biopharmaceutical company. Tyme is focused on the development and commercialization of highly targeted cancer therapeutics with a range of oncology indications. The Company’s another subsidiary, Luminant Biosciences, LLC, conducts the initial research and development of the Company’s therapeutic platform. The Company is formulating its regulatory and drug development program for its lead drug candidate, SM-88, and working towards the initiation of its Phase II clinical trial. The Company is also evaluating the expansion of its Phase II program to other types of cancer. The Company has not generated any revenue.
